- Home
- CYRX vs DCTH Comparison
CYRX vs DCTH Comparison
Compare CYRX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- DCTH
- Stock Information
- Founded
- CYRX 1999
- DCTH 1988
- Country
- CYRX United States
- DCTH United States
- Employees
- CYRX N/A
- DCTH N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- CYRX Health Care
- DCTH Health Care
- Exchange
- CYRX Nasdaq
- DCTH Nasdaq
- Market Cap
- CYRX 365.5M
- DCTH 394.9M
- IPO Year
- CYRX N/A
- DCTH N/A
- Fundamental
- Price
- CYRX $7.27
- DCTH $10.59
- Analyst Decision
- CYRX Strong Buy
- DCTH Strong Buy
- Analyst Count
- CYRX 10
- DCTH 4
- Target Price
- CYRX $10.90
- DCTH $24.00
- AVG Volume (30 Days)
- CYRX 432.7K
- DCTH 717.2K
- Earning Date
- CYRX 08-05-2025
- DCTH 08-06-2025
- Dividend Yield
- CYRX N/A
- DCTH N/A
- EPS Growth
- CYRX N/A
- DCTH N/A
- EPS
- CYRX N/A
- DCTH N/A
- Revenue
- CYRX $232,134,000.00
- DCTH $53,850,000.00
- Revenue This Year
- CYRX N/A
- DCTH $162.10
- Revenue Next Year
- CYRX $9.36
- DCTH $32.97
- P/E Ratio
- CYRX N/A
- DCTH N/A
- Revenue Growth
- CYRX 11.75
- DCTH 1068.87
- 52 Week Low
- CYRX $4.58
- DCTH $7.17
- 52 Week High
- CYRX $9.66
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- CYRX 48.45
- DCTH 30.85
- Support Level
- CYRX $6.70
- DCTH $11.15
- Resistance Level
- CYRX $7.89
- DCTH $11.67
- Average True Range (ATR)
- CYRX 0.42
- DCTH 0.51
- MACD
- CYRX -0.05
- DCTH 0.04
- Stochastic Oscillator
- CYRX 32.57
- DCTH 8.01
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.